Completed Access to Information Requests 2018

• All training documents or training presentations created by or for the PMPRB since January 1, 2015 (whether dealing with the proposed amendments or not).
• The agenda or minutes for all meetings held by the PMPRB executive since January 1, 2015 (whether dealing with the proposed amendments or not).
• Copies of all agreements between the Minister and any province or territory that were entered into pursuant to section 103 of the Patent Act.
• Any reports, memorandums, or similar documents produced since January 1, 2015, and dealing with one or more of the following topics: (i) the effects of provincial price controls on drug prices (patented or unpatented, prescription or non-prescription), (ii) Product Listing Agreements for drugs (on either provincial or federal formularies), or (iii) the pan-Canadian Pharmaceutical Alliance. The whole whether dealing with the proposed amendments or not.
• All documents used to prepare the RIAS.
• Any draft or non-public versions of the RIAS.
• The documents or data used to estimate the costs and benefits discussed in RIAS.
• All documents or data relating to the adoption of the new basket of countries and decision to include/exclude particular countries as part of the proposed amendments.
• All documents or data relating to the adoption of new pricing factors as part of the proposed amendments.
• All documents or data relating to changes in the reporting requirements for patentees as part of the proposed amendments.
• All documents used to support or generate the claim that "Regulating the prices for patented medicines to be non-excessive is not subject to trade provisions" (last sentence of RIAS Executive Summary).
• Draft versions of the PMPRB Compendium of Policies, Guidelines, and Procedures which relate to the proposed amendments, including the new pricing factors and basket of countries.
• All communications regarding the proposed amendments between the PMPRB on the one hand, and on the other hand at least one of the following organizations: Health Canada, ISED, or the Canadian Intellectual Property Office.
• All communications or documents received from provincial or territorial governments regarding the proposed amendments.
• Any provincial or territorial response to any of the following 3 consultations:
• Canada Gazette Part I Consultation Responses - closed February 2018.
• Proposed Amendments to The Patented Medicines Regulations Consultation ­closed June 2017 [Protecting Canadians from Excessive Drug Prices: Consulting on Proposed Amendments to the Patented Medicines Regulations].

PMPRB Rethinking the Guidelines Consultation - closed October 2016.

A copy of all emails sent or received (including attachments) by the person occupying the role of or acting as Chairperson of the PMPRB, and which discuss or relate to the proposed amendments in any way, if sent or received during any of the following periods:

• 1 May 2016 to 14 July 2016
• 1 November 2016 to 11 November 2016
• 1 April 2017 to 14 July 2017
• 1 November 2017 to 31 December 2017
• 15 February 2018 to 28 February 2018

A copy of all emails sent or received (including attachments) by the person occupying the role of or acting as Director, Policy and Economic Analysis of the PMPRB, and which discuss or relate to the proposed amendments in any way, if sent or received during any of the following periods:

• 1 May 2016 to 14 July 2016
• 1 November 2016 to 11 November 2016
• 1 April 2017 to 14 July 2017
• 1 November 2017 to 31 December 2017
• 15 February 2018 to 28 February 2018

Note: To the extent that a copy of the email and its attachments has already been provided in response to our request for emails sent or received by the Chairperson, then we do not require a second copy of that email.

A copy of all emails sent or received (including attachments) by the person occupying the role of or acting as Director, Regulatory Affairs and Outreach of the PMPRB, and which discuss or relate to the proposed amendments in any way, if sent or received during any of the following periods:

• 1 May 2016 to 14 July 2016
• 1 November 2016 to 11 November 2016
• 1 April 2017 to 14 July 20I7
• 1 November 2017 to 31 December 2017
• 15 February 2018 to 28 February 2018

Note: To the extent that a copy of the email and its attachments has already been provided in response to our request for emails sent or received by the Chairperson or the Director, Regulatory Affairs and Outreach, then we do not require a second copy of that email.

1. A copy of the documents provided in response to the following access to information requests:
   • A-2017-000583 I JS3
   • A-2017-00303 I PJ
2. Ministerial or cabinet briefing notes regarding the Patented Medicines Price Review Board (PMPRB) that were prepared since January 1, 2015.
3. Ministerial or cabinet briefing notes regarding the amendments to the Patented Medicines Regulations that were proposed in 201 7. These amendments were published in the Canada Gazette on December 2, 2017.
4. All non-published reports, memos, and documents prepared by the PMPRB since January 1, 2015, and dealing with amendments to the Patented Medicines Regulations.
5. Documents or communications discussing whether the proposed amendments are authorized by the Patent Act.
6. Documents or communications discussing whether the amendments are consistent with past decisions by Canadian courts.
7. Documents or communications discussing whether the amendments are consistent with Canada's international treaty obligations (NAFTA, WTO, etc.).
8. Documents or communications analyzing or estimating the effects of the proposed amendments on the pharmaceutical industry or the healthcare system.
9. All non-privileged documents or communications discussing whether the proposed amendments are consistent with the jurisdiction of the federal government.